Welcome, Introduction, Polling Questions
Introduction: Overview of CLL/SLL and Treatment Algorithms – Dr. Sharman
- Standard-of-care first-line and second-line regimens
- Key variables in deciding between regimens
- Mastering the current regimen components
- On the horizon: measurable residual disease, CAR T-cell therapy, and other hot research areas
Effective Management of CLL by Pharmacists – Dr. Bucholtz
- Starting systemic therapy in suitable patients
- Promoting adherence with oral therapy
- Adverse event profiles and management guides and resources
Summary, Final Thoughts, Audience Q&A
Emily Bucholtz, RPh
Willamette Valley Cancer Institution
Jeff Sharman, MD
US Oncology Research
The goal of this activity is to improve the knowledge and competence of hematology-oncology pharmacists and other healthcare professionals so they can confidently and competently apply the recent improvements in CLL to optimize patient outcomes.
This educational program is intended for hematology-oncology pharmacists and other healthcare providers who care for patients with CLL.
Upon completion of this activity, participants should be able to:
- Discuss treatment plans for treatment-naive and relasped/refractory CLL/SLL, including consideration of agent differences, biomarkers, comorbidities, and patient preference
- Describe intraclass differences for agents with the same target in CLL/SLL regarding selectivity, target binding, efficacy, adverse event profiles
- Formulate strategies to minimize risk for drug–drug interactions with recently approved and emerging systemic therapies in CLL/SLL
- Evaluate the evolving role of measurable residual disease, allogeneic hematopoietic cell transplant, and CAR T-cell therapy
- Develop strategies to address unique challenges (eg, identification and management of adverse events, adherence/compliance to treatment) as well ways hematology-oncology pharmacists optimize outcomes for patients with CLL
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. UAN: JA4008176-0000-21-031-L01-P
Type of Activity: Knowledge
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.